(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.25%) $924.40
(0.36%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $19.46
Utstedt: 14 feb 2024 @ 15:30
Avkastning: 2.67%
Forrige signal: feb 13 - 15:31
Forrige signal:
Avkastning: -3.52 %
Live Chart Being Loaded With Signals
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases...
Stats | |
---|---|
Dagens volum | 355 716 |
Gjennomsnittsvolum | 692 466 |
Markedsverdi | 1.23B |
EPS | $0 ( 2024-02-27 ) |
Neste inntjeningsdato | ( $-0.0900 ) 2024-05-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.61 |
ATR14 | $0.0250 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-09 | Cornelissen Bart Jan | Buy | 190 194 | Stock Option (Right to Buy) |
2024-04-09 | Cornelissen Bart Jan | Buy | 42 265 | Common Stock |
2024-04-09 | Cornelissen Bart Jan | Buy | 0 | |
2024-03-11 | Kuch John J | Sell | 849 | Common Stock |
2024-03-11 | Eckert Celia | Sell | 850 | Common Stock |
INSIDER POWER |
---|
65.95 |
Last 96 transactions |
Buy: 2 831 480 | Sell: 458 022 |
Volum Korrelasjon
Xencor Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
THRX | 0.898 |
WDC | 0.891 |
PALT | 0.886 |
TREE | 0.883 |
OZKAP | 0.882 |
OTRK | 0.881 |
XPEL | 0.873 |
HLMN | 0.871 |
MBIO | 0.869 |
TCBIO | 0.862 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Xencor Inc Korrelasjon - Valuta/Råvare
Xencor Inc Økonomi
Annual | 2023 |
Omsetning: | $168.34M |
Bruttogevinst: | $156.84M (93.17 %) |
EPS: | $-2.08 |
FY | 2023 |
Omsetning: | $168.34M |
Bruttogevinst: | $156.84M (93.17 %) |
EPS: | $-2.08 |
FY | 2022 |
Omsetning: | $164.58M |
Bruttogevinst: | $155.78M (94.65 %) |
EPS: | $-0.930 |
FY | 2021 |
Omsetning: | $275.11M |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $1.440 |
Financial Reports:
No articles found.
Xencor Inc
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.